Wandercraft acquires Ekso Bionics to form global exoskeleton leader
Wandercraft has completed the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation, bringing together two of the most established names in medical exoskeleton development. The transaction was signed and closed simultaneously, with financial terms not disclosed. The combined entity will operate across the full continuum of robotic mobility, from clinical rehabilitation to everyday personal use.
The deal pairs Wandercraft's strength in European and Middle Eastern markets, built around its Atalante X rehabilitation exoskeleton and Eve personal device, with Ekso Bionics' two-decade commercial footprint in the United States and its EksoNR rehabilitation platform and Indego Personal wearable. Together, the four products are deployed at more than 700 rehabilitation centres worldwide and hold regulatory clearances including US FDA clearance and CE marking for indications spanning stroke, spinal cord injury, multiple sclerosis, and acquired brain injury.
The deal
Matthieu Masselin, chief executive and co-founder of Wandercraft, said the combination offers "an exceptional opportunity to expand access to robotic mobility worldwide, reach more patients and rehabilitation professionals, and help more people experience the independence and connection that upright mobility can offer." Scott Davis, speaking on behalf of the go-forward Ekso Bionics business, described the transaction as "an exciting next chapter" for an organisation with a substantial body of clinical evidence underpinning clinician trust in its products.
Wandercraft said it intends to continue supporting all four devices and the clinicians, rehabilitation centres, and individual users who rely on them. The company also highlighted its Walk in New York by Wandercraft rehabilitation centre, where patients are already receiving training, and noted that a dedicated access team assists users in navigating Medicare reimbursement. In the US, qualifying personal exoskeletons are covered under Medicare's brace benefit category via HCPCS code K1007, a reimbursement pathway the combined company intends to leverage and advocate to broaden internationally.
Market context
Medical exoskeletons represent a relatively concentrated segment of the broader medical-device market, with a small number of well-capitalised players competing for hospital procurement budgets and, increasingly, direct-to-consumer personal mobility contracts. The consolidation of Wandercraft and Ekso Bionics removes one axis of transatlantic competition and creates a company with arguably the widest regulatory coverage and geographic distribution in the field.
Competitive pressure is unlikely to ease. ReWalk Robotics and Cyberdyne's HAL system remain active in rehabilitation settings, and a number of earlier-stage startups are pursuing lighter, lower-cost designs that could disrupt the premium rehabilitation-centre model over the medium term. Meanwhile, the integration of so-called physical AI, which Wandercraft deploys across both medical and its industrial Calvin-40 humanoid platform, is becoming a meaningful differentiator as buyers compare the adaptability and sensor responsiveness of next-generation devices.
For Wandercraft, the acquisition offers a shortcut to US commercial infrastructure that organic growth would have taken considerably longer to build. The reimbursement landscape, in particular, rewards incumbents with established documentation and coding expertise, making Ekso Bionics' existing Medicare pathway a tangible commercial asset rather than merely a regulatory formality.
The boards of both Wandercraft and ChronoScale Holdings approved the transaction unanimously. No integration timeline or headcount details were disclosed in the announcement.